Home ›
Trademark Categories ›
Science & Technology Services ›
2015 ›
NI ›
NINLARO 1POINT
Trademark search for:
NINLARO 1POINT
No active United States Patent and Trademark Office (USPTO) registrations found, based on publicly available USPTO trademark records.
Trademark records may change over time.
For the most up-to-date trademark status, domain availability,
and social handle checks, run a live search.
Check latest trademark, domains & social handles
Live search · Most up-to-date results
USPTO Filing History
Key events recorded for this trademark application
2017-02-03 — Application filed
2017-02-07 — Application filed
2017-02-09 — Application filed
2017-02-10 — Notice of design search code e-mailed
2017-05-01 — Assigned to examiner
2017-05-03 — Suspension letter written
2017-05-03 — Letter of suspension e-mailed
2017-05-03 — Notification of letter of suspension e-mailed
2017-11-03 — Report completed suspension check case still suspended
2018-05-03 — Report completed suspension check case still suspended
2018-06-22 — Teas change of correspondence received
2018-11-03 — Report completed suspension check case still suspended
2019-05-04 — Report completed suspension check case still suspended
2019-08-29 — Teas change of correspondence received
2019-09-23 — Teas revoke/app/change addr of atty/dom rep received
2019-09-23 — Attorney/dom.rep.revoked and/or appointed
2019-11-22 — Assigned to lie
2019-12-19 — Suspension checked - to attorney for action
2019-12-26 — Assigned to examiner
2020-01-06 — Application abandoned
2020-01-07 — Application abandoned
2020-01-07 — Application abandoned
2020-01-07 — Final status recorded
Owner Information
Millennium Pharmaceuticals, Inc.
Cambridge , MA
Correspondent
Karl M. Zielaznicki, Esq. Troutman Sanders LLP 875 Third Avenue c/o IP Services NYC New York, NY 10022
Filing Details
Filing Date:
2017-02-03
Status Date:
2020-01-07
Disclaimer: This page is informational only and does not constitute legal advice.
Trademark availability depends on jurisdiction, usage, and legal interpretation.